Maravai LifeSciences (MRVI) Tops Q4 EPS by 7c; Guides Higher

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of $0.45, $0.07 better than the analyst estimate of $0.38. Revenue for the quarter came in at $228.4 million versus the consensus estimate of $208.09 million.

GUIDANCE:

Maravai LifeSciences sees FY2022 EPS of $1.70-$1.84, versus the consensus of $1.54. Maravai LifeSciences sees FY2022 revenue of $920-960 million, versus the consensus of $863.92 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Worthington Industries (WOR) Misses Q4 EPS by 9c
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance